{
    "clinical_study": {
        "@rank": "149795", 
        "arm_group": [
            {
                "arm_group_label": "Low Single Dose Brilacidin", 
                "arm_group_type": "Experimental", 
                "description": "0.6mg/kg Brilacidin IV (single dose) on Day 1, followed by placebo Daily Days 2-7"
            }, 
            {
                "arm_group_label": "High Single Dose Brilacidin", 
                "arm_group_type": "Experimental", 
                "description": "0.8mg/kg Brilacidin IV (single dose)"
            }, 
            {
                "arm_group_label": "3-Day Regimen Brilacidin", 
                "arm_group_type": "Experimental", 
                "description": "0.6mg/kg Brilacidin IV on Day 1, followed by 0.3mg/kg Brilacidin IV on Days 2 & 3"
            }, 
            {
                "arm_group_label": "Standard dosing regimen Daptomycin", 
                "arm_group_type": "Active Comparator", 
                "description": "4mg/kg Daptomycin IV daily for 7 Days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficacy of three different dosing\n      regimens of brilacidin compared to daptomycin for the treatment of serious skin infections.\n      This study will aid in selecting the appropriate dose of brilacidin for later stage studies."
        }, 
        "brief_title": "Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Skin Infection", 
            "Bacterial Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Skin Diseases, Infectious"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, multi-center, double-blind study to evaluate the efficacy and safety\n      of three regimens of brilacidin compared to an active control, daptomycin, in subjects with\n      ABSSSI. Subjects must have infections that warrant intravenous therapy but may be treated as\n      either inpatients or outpatients.\n\n      Eligible subjects will be randomized to one of 4 treatment groups in a 1:1:1:1 ratio.\n      Subjects randomized to brilacidin will receive either a single intravenous infusion (0.6\n      mg/kg or 0.8 mg/kg) followed by six days of once daily placebo, or a three day regimen (0.6\n      mg/kg on Day 1 followed by 0.3 mg/kg on Days 2 and 3) followed by 4 days of once daily\n      placebo.  Subjects randomized to daptomycin will receive 7 days of treatment. Subjects will\n      be assessed for both clinical and microbiologic efficacy 48-72 hours after the first dose of\n      study drug. After an assessment at Day 7-8, subjects will be again be evaluated for efficacy\n      at Day 10-14 and via a phone contact at Day 21-28.\n\n      Approximately 200 subjects randomized in a 1:1:1:1 ratio to receive one of the three\n      brilacidin regimens or daptomycin will be evaluable. The primary efficacy outcome, early\n      clinical response 48-72 hours after the first dose of study drug, will be determined in the\n      Intent-to treat (ITT) population. Additional efficacy and safety analyses will be performed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of written informed consent\n\n          -  Be  \u2265 18 and \u2264 85 years of age\n\n          -  Have one of the following types of ABSSSI:\n\n               1. A post-traumatic or post-surgical wound infection, occurring within 30 days of\n                  the trauma or surgery, characterized by purulent or seropurulent drainage from\n                  the wound and surrounding erythema, edema and/or induration of a minimum surface\n                  area of 75 cm2.\n\n               2. A major cutaneous abscess, characterized by a collection of pus within the\n                  dermis or deeper tissues, accompanied by erythema, edema, and/or induration of a\n                  minimum surface area of 75 cm2. Note: patients with major cutaneous abscess will\n                  be limited to 30% of total enrollment\n\n               3. Cellulitis/erysipelas,  characterized  by  spreading  areas  of  erythema,\n                  edema, and/or induration of a minimum surface area of 75 cm2.\n\n          -  Have two or more of the following signs:\n\n               1. Purulent or seropurulent drainage or discharge\n\n               2. Erythema\n\n               3. Fluctuance\n\n               4. Heat or localized warmth\n\n               5. Pain or tenderness to palpation\n\n          -  Have one or more of the following systemic signs:\n\n               1. Temperature  (oral  or   tympanic)  \u2265   38\u2070   C/100.4  F,   as   measured  by\n                  the subject/caregiver or investigator up to 24 hours prior to baseline\n\n               2. WBC count > 10,000/mm3\n\n               3. Greater than 10% bands or other immature neutrophils (total), irrespective of\n                  WBC count\n\n               4. Elevated C-reactive protein (CRP) (> 40 mg/L), if tested\n\n               5. Presence of lymphadenitis or lymphadenopathy proximal to the infected area\n\n          -  Must not have received more than a single dose of a short-acting systemic antibiotic\n             for the current ABSSSI within 72 hours prior to randomization, unless either of the\n             following situations apply:\n\n               1. Clinical evidence of treatment failure following at least 48 hours of prior\n                  systemic antimicrobial therapy; or\n\n               2. The subject recently completed a course of antibiotic treatment for an infection\n                  other than ABSSSI and that drug is not active against the bacterial pathogens\n                  that typically cause ABSSSI.\n\n        Exclusion Criteria:\n\n          -  Female subjects who are pregnant, lactating (breast milk feeding), or planning a\n             pregnancy during the course of the study.\n\n          -  Skin or skin structure infection with any of the following characteristics:\n\n               1. Presence  of  an  uncomplicated  skin  or  skin  structure  infection,  such  as\n                  folliculitis, furunculosis, or minor abscess likely to respond to incision and\n                  drainage alone\n\n               2. Suspected or confirmed osteomyelitis\n\n               3. Suspected or confirmed septic arthritis\n\n               4. Suspected  or  confirmed  infection  caused  exclusively  by  Gram-negative\n                  pathogens or by any anaerobes\n\n          -  Known hypersensitivity to daptomycin\n\n          -  Known creatinine clearance <50 mL/min (based on the Cockcroft-Gault formula using\n             ideal body weight)\n\n          -  Immunosuppression, defined as chronic corticosteroid use (20 mg prednisone/day or\n             equivalent), solid   organ   or   bone   marrow   transplantation,   current\n             cytotoxic chemotherapy, neutropenia (absolute neutrophil count < 500/mm3), or known\n             HIV infection with CD4+ count < 200/mm3\n\n          -  Platelet count <50 x 103/L\n\n          -  Exhibits signs of sepsis:\n\n               1. Shock or profound hypotension, defined as systolic blood pressure <90 mm Hg or a\n                  decrease of >40 mm Hg from baseline that is not responsive to fluid challenge;\n\n               2. Hypothermia (core temperature <35.6\u00b0C or <96.1\u00b0F);\n\n               3. Disseminated intravascular coagulation as evidenced by prothrombin time (PT) or\n                  activated partial thromboplastin time (aPTT) 2 times the upper limit of normal;\n\n          -  Inability or unwillingness to adhere to the study-specified procedures and\n             restrictions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "215", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052388", 
            "org_study_id": "CTIX-BRI-204"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard dosing regimen Daptomycin", 
                "description": "Active Comparator", 
                "intervention_name": "Daptomycin", 
                "intervention_type": "Drug", 
                "other_name": "Cubicin"
            }, 
            {
                "arm_group_label": [
                    "Low Single Dose Brilacidin", 
                    "High Single Dose Brilacidin", 
                    "3-Day Regimen Brilacidin"
                ], 
                "description": "Experimental Drug", 
                "intervention_name": "Brilacidin", 
                "intervention_type": "Drug", 
                "other_name": "Brilacidin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Daptomycin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Skin Infection", 
            "Staph aureus", 
            "MRSA", 
            "MSSA", 
            "Cellulitis/Erysipelas", 
            "Wound Infection", 
            "Abscess"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91911"
                    }, 
                    "name": "eStudy Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Mesa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91942"
                    }, 
                    "name": "eStudy Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92056"
                    }, 
                    "name": "eStudy Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89109"
                    }, 
                    "name": "eStudy Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)", 
        "other_outcome": {
            "description": "Brilacidin levels will be determined  at specified times to aid in pharmacokinetic-pharmacodynamic analyses. These data will aid in dose selection for later stage trials.", 
            "measure": "Plasma drug levels", 
            "safety_issue": "No", 
            "time_frame": "Days 1 (peak), 2 (trough) and 3 (trough and peak)"
        }, 
        "overall_official": {
            "affiliation": "eStudy SIte", 
            "last_name": "William O'Riordan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy outcome, early clinical response 48-72 hours after the first dose of study drug, will be determined in the ITT population.  A subject will be considered a Clinical Success if 1) the lesion area has decreased by \u226520% compared to baseline and 2) no additional systemic antibacterials that are potentially effective against gram positive organisms have been administered.", 
            "measure": "Early clinical response", 
            "safety_issue": "No", 
            "time_frame": "48-72 hours after first dose of study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052388"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "For Days 7/8 and  10-14, a response of Clinical Success will be assigned if all signs and symptoms of infection present at  baseline  have  improved  and/or  resolved  and  no  additional  antibiotics  are considered necessary.\nSubjects  who  have  a  response  of  Clinical  Success  at  Day 10-14  will  be  assessed for sustained efficacy  at Day 21-28. A response of Sustained Clinical Success will be assigned if all signs and symptoms remain resolved and no additional antibiotics are considered necessary.  If signs and symptoms of infection recurred at the original site of infection and require additional antibiotic therapy, a response of Relapse will be assigned.", 
                "measure": "Clinical Response", 
                "safety_issue": "No", 
                "time_frame": "Day 7-8; Day 10-14; Day 21-28"
            }, 
            {
                "description": "Microbiological responses for those subjects who had a relevant skin pathogen isolated at baseline (MITT and ME populations)", 
                "measure": "Microbiological response", 
                "safety_issue": "No", 
                "time_frame": "48-72 hours; Day 7-8; Day 10-14"
            }
        ], 
        "source": "Cellceutix Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cellceutix Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}